We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+4.87%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$1.7B
AUM Growth
-$254M
Cap. Flow
-$154M
Cap. Flow %
-9.05%
Top 10 Hldgs %
40.6%
Holding
107
New
9
Increased
39
Reduced
24
Closed
7

Top Buys

Rank Stock Value
1
MMED
MiniMed Group Inc
MMED
+$17.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$15M
3
BSX icon
Boston Scientific
BSX
+$9.3M
4
HTFL
Heartflow Inc
HTFL
+$8M
5
PTCT icon
PTC Therapeutics
PTCT
+$7.08M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$61.1M
2
CDTX
Cidara Therapeutics
CDTX
+$45.3M
3
FOLD
Amicus Therapeutics
FOLD
+$27.4M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$24M
5
TVTX icon
Travere Therapeutics
TVTX
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
2 Miscellaneous 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
76
Ocular Therapeutix
OCUL
$2.28B
$3.25M 0.19%
383,716
+37,896
+11% +$361K
VKTX icon
77
Viking Therapeutics
VKTX
$3.75B
$3.12M 0.18%
+96,000
New +$3.09M
CYTK icon
78
Cytokinetics
CYTK
$10B
$2.99M 0.18%
45,364
+9,511
+27% +$604K
IPSC icon
79
Century Therapeutics
IPSC
$367M
$2.95M 0.17%
+1,304,347
New +$2.74M
CVS icon
80
CVS Health
CVS
$119B
$2.87M 0.17%
+40,000
New +$3.08M
ROIV icon
81
Roivant Sciences
ROIV
$25.1B
$2.69M 0.16%
97,000
+8,250
+9% +$212K
TLPH icon
82
Talphera
TLPH
$62.3M
$2.68M 0.16%
3,589,186
– –
OLMA icon
83
Olema Pharmaceuticals
OLMA
$899M
$2.54M 0.15%
170,378
+72,138
+73% +$1.61M
SGRY icon
84
Surgery Partners
SGRY
$1.79B
$2.48M 0.15%
208,000
-102,000
-33% -$1.46M
LENZ
85
LENZ Therapeutics
LENZ
$161M
$2.36M 0.14%
257,460
– –
EW icon
86
Edwards Lifesciences
EW
$52B
$2.31M 0.14%
28,900
-53,600
-65% -$4.42M
DNTH icon
87
Dianthus Therapeutics
DNTH
$5.92B
$2.25M 0.13%
+26,757
New +$1.55M
NGNE icon
88
Neurogene
NGNE
$732M
$2.1M 0.12%
104,339
– –
AGL icon
89
Agilon Health
AGL
$1.55B
$2.06M 0.12%
260,000
– –
CORT icon
90
Corcept Therapeutics
CORT
$12.3B
$2.03M 0.12%
50,250
– –
ACHC icon
91
Acadia Healthcare
ACHC
$2.66B
$1.77M 0.1%
75,500
-44,500
-37% -$806K
TEVA icon
92
Teva Pharmaceuticals
TEVA
$42.5B
$1.37M 0.08%
45,500
– –
MLTX icon
93
MoonLake Immunotherapeutics
MLTX
$1.28B
$1.15M 0.07%
61,700
– –
JAZZ icon
94
Jazz Pharmaceuticals
JAZZ
$15.9B
$1.09M 0.06%
5,750
+4,000
+229% +$699K
JSPR icon
95
Jasper Therapeutics
JSPR
$23.3M
$964K 0.06%
1,100,726
– –
LEGN icon
96
Legend Biotech
LEGN
$3.87B
$733K 0.04%
40,500
+6,700
+20% +$128K
GOSS icon
97
Gossamer Bio
GOSS
$83.2M
$529K 0.03%
1,609,492
-1,657,468
-51% -$2.61M
FOLD
98
DELISTED
Amicus Therapeutics
FOLD
$305K 0.02%
21,062
-1,908,869
-99% -$27.4M
ORKA
99
Oruka Therapeutics
ORKA
$6.03B
$202K 0.01%
+4,123
New +$143K
BCRX icon
100
BioCryst Pharmaceuticals
BCRX
$2.51B
$120K 0.01%
+12,600
New +$97.8K
1 2 3
4
5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Rock Springs Capital Management held 107 positions worth $1.7B, down 13% from $1.95B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Rock Springs Capital Management withdrew a net $154M in Q1 2026, closing 7 positions and reducing 24 holdings. Its most notable exit was Exact Sciences, an estimated $61.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Rock Springs Capital Management opened a new position in MiniMed Group Inc worth $15.7M.

  • Rock Springs Capital Management's largest Q1 2026 buy was MiniMed Group Inc: 1,055,000 shares worth $15.7M.
  • Rock Springs Capital Management added most to Madrigal Pharmaceuticals in Q1 2026, an estimated $15M increase.
  • Rock Springs Capital Management's biggest Q1 2026 reduction was Amicus Therapeutics, cutting an estimated $27.4M.
  • Rock Springs Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $61.1M.
  • Rock Springs Capital Management's ten largest holdings make up 41% of its $1.7B portfolio in Q1 2026.
  • Rock Springs Capital Management opened 9 new positions and closed 7 in Q1 2026.
  • Rock Springs Capital Management's portfolio value fell 13% quarter-over-quarter to $1.7B.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.